1044 related articles for article (PubMed ID: 26349000)
21. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome.
de Pagter PJ; Schuurman R; Visscher H; de Vos M; Bierings M; van Loon AM; Uiterwaal CS; van Baarle D; Sanders EA; Boelens J
Biol Blood Marrow Transplant; 2008 Jul; 14(7):831-9. PubMed ID: 18541204
[TBL] [Abstract][Full Text] [Related]
22. Clinical-grade varicella zoster virus-specific T cells produced for adoptive immunotherapy in hemopoietic stem cell transplant recipients.
Blyth E; Gaundar SS; Clancy L; Simms RM; Bilmon I; Micklethwaite KP; Gottlieb DJ
Cytotherapy; 2012 Jul; 14(6):724-32. PubMed ID: 22404084
[TBL] [Abstract][Full Text] [Related]
23. Serology indicates cytomegalovirus infection is associated with varicella-zoster virus reactivation.
Ogunjimi B; Theeten H; Hens N; Beutels P
J Med Virol; 2014 May; 86(5):812-9. PubMed ID: 24037981
[TBL] [Abstract][Full Text] [Related]
24. Allotype analysis to distinguish the origin of varicella-zoster virus immunoglobulin G after allogeneic stem cell transplantation.
Yamazaki R; Nakasone H; Tanaka Y; Sato M; Terasako K; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Ashizawa M; Machishima T; Kimura S; Kikuchi M; Okuda S; Kako S; Kanda J; Tanihara A; Nishida J; Kanda Y
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1013-20. PubMed ID: 23583826
[TBL] [Abstract][Full Text] [Related]
25. Adoptive immunotherapy with virus-specific T cells.
Fuji S; Kapp M; Grigoleit GU; Einsele H
Best Pract Res Clin Haematol; 2011 Sep; 24(3):413-9. PubMed ID: 21925094
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation.
Micklethwaite KP; Clancy L; Sandher U; Hansen AM; Blyth E; Antonenas V; Sartor MM; Bradstock KF; Gottlieb DJ
Blood; 2008 Nov; 112(10):3974-81. PubMed ID: 18768783
[TBL] [Abstract][Full Text] [Related]
27. First-in-man clinical results with good manufacturing practice (GMP)-compliant polypeptide-expanded adenovirus-specific T cells after haploidentical hematopoietic stem cell transplantation.
Geyeregger R; Freimüller C; Stemberger J; Artwohl M; Witt V; Lion T; Fischer G; Lawitschka A; Ritter J; Hummel M; Holter W; Fritsch G; Matthes-Martin S
J Immunother; 2014 May; 37(4):245-9. PubMed ID: 24714358
[TBL] [Abstract][Full Text] [Related]
28. Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.
Galletta TJ; Lane A; Lutzko C; Leemhuis T; Cancelas JA; Khoury R; Wang YM; Hanley PJ; Keller MD; Bollard CM; Davies SM; Grimley MS; Rubinstein JD
Transplant Cell Ther; 2023 May; 29(5):305-310. PubMed ID: 36736781
[TBL] [Abstract][Full Text] [Related]
29. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
30. Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease.
Gotoh M; Yoshizawa S; Katagiri S; Suguro T; Asano M; Kitahara T; Akahane D; Okabe S; Tauchi T; Ito Y; Ohyashiki K
Transpl Infect Dis; 2014 Jun; 16(3):440-9. PubMed ID: 24810656
[TBL] [Abstract][Full Text] [Related]
31. Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study.
Gerbitz A; Gary R; Aigner M; Moosmann A; Kremer A; Schmid C; Hirschbuehl K; Wagner E; Hauptrock B; Teschner D; Roesler W; Spriewald B; Tischer J; Moi S; Balzer H; Schaffer S; Bausenwein J; Wagner A; Schmidt F; Brestrich J; Ullrich B; Maas S; Herold S; Strobel J; Zimmermann R; Weisbach V; Hansmann L; Lammoglia-Cobo F; Remberger M; Stelljes M; Ayuk F; Zeiser R; Mackensen A
Front Immunol; 2023; 14():1251593. PubMed ID: 37965339
[TBL] [Abstract][Full Text] [Related]
32. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
33. Lymphoproliferative response to herpes simplex virus type 1, cytomegalovirus, Epstein-Barr virus, varicella zoster virus, human herpes virus 6, 7, and 8 antigen stimulation in pediatric allogeneic stem cell transplant recipients.
Cheng FW; Chan PK; Lee V; Leung WK; Shing MK; Li CK; Leung TF
Pediatr Transplant; 2010 Sep; 14(6):761-9. PubMed ID: 20534025
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.
Ding Y; Ru Y; Song T; Guo L; Zhang X; Zhu J; Li C; Jin Z; Huang H; Tu Y; Xu M; Xu Y; Chen J; Wu D
Ann Hematol; 2021 Nov; 100(11):2773-2785. PubMed ID: 34480615
[TBL] [Abstract][Full Text] [Related]
35. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
36. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.
Lugthart G; van Ostaijen-Ten Dam MM; Jol-van der Zijde CM; van Holten TC; Kester MG; Heemskerk MH; Bredius RG; van Tol MJ; Lankester AC
Biol Blood Marrow Transplant; 2014 May; 20(5):655-61. PubMed ID: 24462981
[TBL] [Abstract][Full Text] [Related]
37. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.
Icheva V; Kayser S; Wolff D; Tuve S; Kyzirakos C; Bethge W; Greil J; Albert MH; Schwinger W; Nathrath M; Schumm M; Stevanovic S; Handgretinger R; Lang P; Feuchtinger T
J Clin Oncol; 2013 Jan; 31(1):39-48. PubMed ID: 23169501
[TBL] [Abstract][Full Text] [Related]
38. Epidemiology of viral infections among children undergoing hematopoietic stem cell transplant: Α prospective single-center study.
Tsoumakas K; Giamaiou K; Goussetis E; Graphakos S; Kossyvakis A; Horefti E; Mentis A; Elefsiniotis I; Pavlopoulou ID
Transpl Infect Dis; 2019 Aug; 21(4):e13095. PubMed ID: 30993823
[TBL] [Abstract][Full Text] [Related]
39. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation.
Blyth E; Clancy L; Simms R; Ma CK; Burgess J; Deo S; Byth K; Dubosq MC; Shaw PJ; Micklethwaite KP; Gottlieb DJ
Blood; 2013 May; 121(18):3745-58. PubMed ID: 23435462
[TBL] [Abstract][Full Text] [Related]
40. A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy.
Spielmann G; Bollard CM; Kunz H; Hanley PJ; Simpson RJ
Sci Rep; 2016 May; 6():25852. PubMed ID: 27181409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
